Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$76.94Price
Low $109.15
Mid $139.77
High $170.49
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.
Intangible assets via unmatched patent
Intangible assets via unmatched patent portfolio and brand loyalty.
High switching costs for veterinary
High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
Cycle upside
Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.
Our financial-history view of ZTS (ZTS) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.
The revenue trajectory is reported in the financial-history section with year-over-year growth rates. Direction and acceleration are summarised inline; the full table sits within the parent financials tab.
We track operating income alongside operating margin so the reader can separate top-line growth from operating leverage. The numbers analysis subsection flags one-offs, restructuring, and stock-based-compensation effects when material.
Net income is shown together with EPS so dilution and buybacks are visible alongside profit. Where reported net income diverges materially from operating cash flow, the discrepancy is called out in the numbers-analysis subsection.
FAQ
ZTS — frequently asked questions
Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Our composite fair-value range for ZTS is $109–$170, with a midpoint of $140. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for ZTS's archetype.
Our current rating for ZTS is Strong Buy with a confidence score of 88/100. Strong Buy. Zoetis represents an extreme value dislocation for a premier mature compounder. The $139.77 composite fair value provides massive upside against irrational market pessimism. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for ZTS are: Margin Contraction; Livestock Headwinds; Macro Demand Shock. The single biggest risk is Margin Contraction: Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.
Our current rating for ZTS is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($109–$170) versus the current price of $76.9.
ZTS is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ZTS.